Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:119:108146.
doi: 10.1016/j.jsat.2020.108146. Epub 2020 Sep 22.

A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder

Katharine Cioe  1 , Breanne E Biondi  2 , Rebecca Easly  1 , Amanda Simard  1 , Xiao Zheng  3 , Sandra A Springer  4
Affiliations

A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder

Katharine Cioe et al. J Subst Abuse Treat. 2020 Dec.

Abstract

Background: The opioid epidemic is a public health crisis. Medications for opioid use disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release naltrexone (XR-NTX). Research should investigate patients' and providers' perspectives of MOUD since they can influence prescription, retention, and recovery.

Methods: This systematic review focused on patients' and providers' perceptions of MOUD. The review eligibility criteria included inclusion of the outcome of interest, in English, and involving persons ≥18 years. A PubMed database search yielded 1692 results; we included 152 articles in the final review.

Results: There were 63 articles about buprenorphine, 115 articles about methadone, and 16 about naltrexone. Misinformation and stigma associated with MOUD were common patient themes. Providers reported lack of training and resources as barriers to MOUD.

Conclusion: This review suggests that patients have significant misinformation regarding MOUD. Due to the severity of the opioid epidemic, research must consider the effects of patients' and providers' perspectives on treatment for OUD, including the effects on the type of MOUD prescribed, patient retention and adherence, and ultimately the number of patients treated for OUD, which will aid in curbing the opioid epidemic.

Keywords: Buprenorphine/naloxone; MOUD, buprenorphine; Methadone; Opioid use disorder; XR-naltrexone.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow Diagram
See this image and copyright information in PMC

References

    1. A Yokell M, D Zaller N, C Green T, & D Rich J (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Current Drug Abuse Reviews, 4(1), 28–41. - PMC - PubMed
    1. Abraham AJ, Andrews CM, Harris SJ, & Friedmann PD (2020). Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics, 17(1), 55–69. - PMC - PubMed
    1. Adminstration, S. A. a. M. H. S. (2016). Decisions in Recovery: Medications for Opioid Use Disorder. Retrieved from: Available from http://www.samhsa.gov/brss-tacs/shared-decision-making. (Accessed 2016).
    1. Akoul GM (1998). Perpetuating passivity: reliance and reciprocal determinism in physician-patient interaction. Journal of Health Communication, 3(3), 233–259. - PubMed
    1. Alanis-Hirsch K, Croff R, Ford JH 2nd, Johnson K, Chalk M, Schmidt L, & McCarty D (2016). Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. Journal of Substance Abuse Treatment, 62, 68–73. - PMC - PubMed

Publication types

MeSH terms